Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme

James W. Welsh, Ron K. Ellsworth, Rachit Kumar, Kyle Fjerstad, Jesse D Martinez, Raymond B. Nagel, Jennifer Eschbacher, Baldassarre Stea

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: Treatment of glioblastoma multiforme (GBM) continues to pose a significant therapeutic challenge, with most tumors recurring within the previously irradiated tumor bed. To improve outcomes, we must be able to identify and treat resistant cell populations. Rad51, an enzyme involved in homologous recombinational repair, leads to increased resistance of tumor cells to cytotoxic treatments such as radiotherapy. We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival. Methods and Materials: A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated; for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray. Rad51 protein expression was then correlated with the actual and predicted survival using recursive partitioning analysis. Results: Rad51 protein was elevated in 53% of the GBM specimens at surgery. The Rad51 levels correlated directly with survival, with a median survival of 15 months for patients with elevated Rad51 compared with 9 months for patients with low or absent levels of Rad51 (p = .05). At disease recurrence, 70% of patients had additional increases in Rad51 protein. Increased Rad51 levels at disease recurrence similarly predicted for improved overall survival, with a mean survival of 16 months from the second craniotomy compared with only 4 months for patients with low Rad51 levels (p = .13). Conclusion: Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence.

Original languageEnglish (US)
Pages (from-to)1251-1255
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume74
Issue number4
DOIs
StatePublished - Jul 15 2009

Fingerprint

Glioblastoma
proteins
Survival
tumors
Proteins
Neoplasms
Recurrence
Recombinational DNA Repair
Craniotomy
surgery
DNA Repair
enzymes
beds
radiation therapy
Radiotherapy
Therapeutics
deoxyribonucleic acid
DNA
Enzymes
Population

Keywords

  • DNA repair
  • Glioblastoma multiforme
  • Rad51

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme. / Welsh, James W.; Ellsworth, Ron K.; Kumar, Rachit; Fjerstad, Kyle; Martinez, Jesse D; Nagel, Raymond B.; Eschbacher, Jennifer; Stea, Baldassarre.

In: International Journal of Radiation Oncology Biology Physics, Vol. 74, No. 4, 15.07.2009, p. 1251-1255.

Research output: Contribution to journalArticle

Welsh, James W. ; Ellsworth, Ron K. ; Kumar, Rachit ; Fjerstad, Kyle ; Martinez, Jesse D ; Nagel, Raymond B. ; Eschbacher, Jennifer ; Stea, Baldassarre. / Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 74, No. 4. pp. 1251-1255.
@article{ef86d608fd5f441ab012b69ec78c4de3,
title = "Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme",
abstract = "Purpose: Treatment of glioblastoma multiforme (GBM) continues to pose a significant therapeutic challenge, with most tumors recurring within the previously irradiated tumor bed. To improve outcomes, we must be able to identify and treat resistant cell populations. Rad51, an enzyme involved in homologous recombinational repair, leads to increased resistance of tumor cells to cytotoxic treatments such as radiotherapy. We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival. Methods and Materials: A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated; for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray. Rad51 protein expression was then correlated with the actual and predicted survival using recursive partitioning analysis. Results: Rad51 protein was elevated in 53{\%} of the GBM specimens at surgery. The Rad51 levels correlated directly with survival, with a median survival of 15 months for patients with elevated Rad51 compared with 9 months for patients with low or absent levels of Rad51 (p = .05). At disease recurrence, 70{\%} of patients had additional increases in Rad51 protein. Increased Rad51 levels at disease recurrence similarly predicted for improved overall survival, with a mean survival of 16 months from the second craniotomy compared with only 4 months for patients with low Rad51 levels (p = .13). Conclusion: Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence.",
keywords = "DNA repair, Glioblastoma multiforme, Rad51",
author = "Welsh, {James W.} and Ellsworth, {Ron K.} and Rachit Kumar and Kyle Fjerstad and Martinez, {Jesse D} and Nagel, {Raymond B.} and Jennifer Eschbacher and Baldassarre Stea",
year = "2009",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2009.03.018",
language = "English (US)",
volume = "74",
pages = "1251--1255",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Rad51 Protein Expression and Survival in Patients with Glioblastoma Multiforme

AU - Welsh, James W.

AU - Ellsworth, Ron K.

AU - Kumar, Rachit

AU - Fjerstad, Kyle

AU - Martinez, Jesse D

AU - Nagel, Raymond B.

AU - Eschbacher, Jennifer

AU - Stea, Baldassarre

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Purpose: Treatment of glioblastoma multiforme (GBM) continues to pose a significant therapeutic challenge, with most tumors recurring within the previously irradiated tumor bed. To improve outcomes, we must be able to identify and treat resistant cell populations. Rad51, an enzyme involved in homologous recombinational repair, leads to increased resistance of tumor cells to cytotoxic treatments such as radiotherapy. We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival. Methods and Materials: A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated; for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray. Rad51 protein expression was then correlated with the actual and predicted survival using recursive partitioning analysis. Results: Rad51 protein was elevated in 53% of the GBM specimens at surgery. The Rad51 levels correlated directly with survival, with a median survival of 15 months for patients with elevated Rad51 compared with 9 months for patients with low or absent levels of Rad51 (p = .05). At disease recurrence, 70% of patients had additional increases in Rad51 protein. Increased Rad51 levels at disease recurrence similarly predicted for improved overall survival, with a mean survival of 16 months from the second craniotomy compared with only 4 months for patients with low Rad51 levels (p = .13). Conclusion: Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence.

AB - Purpose: Treatment of glioblastoma multiforme (GBM) continues to pose a significant therapeutic challenge, with most tumors recurring within the previously irradiated tumor bed. To improve outcomes, we must be able to identify and treat resistant cell populations. Rad51, an enzyme involved in homologous recombinational repair, leads to increased resistance of tumor cells to cytotoxic treatments such as radiotherapy. We hypothesized that Rad51 might contribute to GBM's apparent radioresistance and consequently influence survival. Methods and Materials: A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated; for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray. Rad51 protein expression was then correlated with the actual and predicted survival using recursive partitioning analysis. Results: Rad51 protein was elevated in 53% of the GBM specimens at surgery. The Rad51 levels correlated directly with survival, with a median survival of 15 months for patients with elevated Rad51 compared with 9 months for patients with low or absent levels of Rad51 (p = .05). At disease recurrence, 70% of patients had additional increases in Rad51 protein. Increased Rad51 levels at disease recurrence similarly predicted for improved overall survival, with a mean survival of 16 months from the second craniotomy compared with only 4 months for patients with low Rad51 levels (p = .13). Conclusion: Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence.

KW - DNA repair

KW - Glioblastoma multiforme

KW - Rad51

UR - http://www.scopus.com/inward/record.url?scp=67649519724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649519724&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.03.018

DO - 10.1016/j.ijrobp.2009.03.018

M3 - Article

C2 - 19545791

AN - SCOPUS:67649519724

VL - 74

SP - 1251

EP - 1255

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -